These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 6619046

  • 21. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
    Kampf D, Borner K, Möller M, Kessel M.
    Clin Pharmacol Ther; 1984 Feb; 35(2):214-20. PubMed ID: 6319069
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP, Rigault JP, Gevaudan MJ, Saingra S, Murisasco A, Charpin J.
    Nouv Presse Med; 1982 Feb 04; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.
    Giron JA, Meyers BR, Hirschman SZ, Srulevitch E.
    Antimicrob Agents Chemother; 1981 Feb 04; 19(2):279-83. PubMed ID: 6214987
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
    Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR.
    Antimicrob Agents Chemother; 1992 Jul 04; 36(7):1532-7. PubMed ID: 1510451
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S, Borgå O, Edenius C, Jostell KG, Odergren T, Weil A.
    Eur J Clin Pharmacol; 2002 Sep 04; 58(6):409-15. PubMed ID: 12242600
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP.
    Eur J Clin Pharmacol; 1987 Sep 04; 31(5):589-93. PubMed ID: 3830244
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E.
    Drugs Exp Clin Res; 1993 Sep 04; 19(1):25-32. PubMed ID: 8223137
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of rufloxacin in patients with impaired renal function.
    Perry G, Mant TG, Morrison PJ, Sacks S, Woodcook J, Wise R, Imbimbo BP.
    Antimicrob Agents Chemother; 1993 Apr 04; 37(4):637-41. PubMed ID: 8388194
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.